GlassScriptPhysician profile
Scott R Kimber
NPI 1548233927
$3,445.71
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $69.20 · 2020: $362 · 2021: $657 · 2022: $738 · 2023: $975 · 2024: $644.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,619.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,619.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $720.67 | 2020-2024 | Otezla, Repatha, Prolia |
| Abbvie INC. | $491.94 | 2021-2024 | |
| Lilly USA, LLC | $418.11 | 2021-2024 | Mounjaro, Trulicity, Jardiance |
| Astrazeneca Pharmaceuticals LP | $332.95 | 2020-2024 | Farxiga, Airsupra |
| Novo Nordisk INC | $317.06 | 2020-2024 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $221.68 | 2019-2024 | Spiriva Respimat, Stiolto Respimat |
| Bayer Healthcare Pharmaceuticals INC. | $130.02 | 2022-2024 | |
| Pfizer INC. | $91.68 | 2019-2024 | |
| Astellas Pharma US INC | $79.05 | 2022-2023 | Veozah, Myrbetriq |
| Takeda Pharmaceuticals U.S.A., INC. | $73.46 | 2022-2023 | Trintellix |
| Biohaven Pharmaceutical Holding Company LTD. | $68.50 | 2022 | |
| Eisai INC. | $62.22 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $57.70 | 2019-2024 | |
| Supernus Pharmaceuticals, INC. | $41.40 | 2021 | |
| Currax Pharmaceuticals LLC | $40.85 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $30.27 | 2023-2024 | Auvelity |
| Janssen Pharmaceuticals, INC | $27.35 | 2020-2024 | Xarelto |
| Sanofi Pasteur INC. | $27.12 | 2023 | |
| Allergan, INC. | $26.43 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $24.53 | 2021 | |
| Welch Allyn | $24.38 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $23.75 | 2021 | |
| Sanofi-Aventis U.S. LLC | $21.64 | 2020 | |
| Phathom Pharmaceuticals, INC. | $19.21 | 2024 | Voquezna |
| Impel Pharmaceuticals INC. | $16.76 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $16.39 | 2022 | |
| Esperion Therapeutics, INC. | $12.71 | 2021 | |
| Mylan Specialty L.P. | $12.57 | 2021 | |
| Glaxosmithkline, LLC. | $10.99 | 2020 | |
| Sumitomo Pharma America, INC. | $4.32 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Kimber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.